Vice President – AI Strategy & Execution Lead
About the job
- Experience working with AI, machine learning, generative AI, data science, analytics, or related technologies.
- Strong understanding of AI solution design, model evaluation, data requirements, testing, deployment, and ongoing monitoring.
- Experience translating business requirements into technology-enabled solutions.
- Strong stakeholder management skills, with the ability to partner effectively across business, technology, governance, and control functions.
- Excellent communication skills, including the ability to explain technical concepts to non-technical audiences and present effectively to senior stakeholders.
- Strong analytical, problem-solving, and project execution skills.
- Ability to operate in a highly controlled, regulated, and fast-paced environment.
- AI Strategy and Roadmap Support: Support the development and execution of the Risk department’s AI strategy, roadmap, operating model, and implementation plan.
- AI Strategy and Roadmap Support: Partner with Risk leadership and subject matter experts to identify AI opportunities across risk management processes.
- AI Strategy and Roadmap Support: Help evaluate, prioritize, and assess the feasibility, value, and adoption potential of AI use cases within Risk.
- AI Strategy and Roadmap Support: Contribute to the articulation of Risk’s AI strategy, progress, opportunities, and risks for senior management audiences.
- AI Use Case Development and Execution: Work with Risk subject matter experts to define and execute prioritized AI use cases.
- AI Use Case Development and Execution: Translate business requirements into scalable, practical AI solutions.
- AI Use Case Development and Execution: Advise on appropriate AI models, tools, technologies, and solution approaches based on business needs, data availability, control requirements, and enterprise standards.
- AI Use Case Development and Execution: Support the full AI use case lifecycle, including ideation, requirements gathering, solution design, testing, deployment, enhancement, and ongoing monitoring.
- Partnership with Technology Teams: Collaborate closely with relevant Technology teams to support AI solution development, integration, testing, and enterprise deployment.
- Partnership with Technology Teams: Help ensure AI solutions are scalable, maintainable, secure, and aligned with enterprise technology architecture and standards.
- Partnership with Technology Teams: Serve as a bridge between Risk stakeholders and Technology teams to ensure clear communication of requirements, constraints, priorities, and delivery timelines.
- AI Adoption, Training, and Change Management: Promote AI adoption across the Risk department by educating stakeholders on AI capabilities, limitations, and relevant use cases.
- AI Adoption, Training, and Change Management: Monitor and communicate developments in AI technology, industry trends, and emerging best practices relevant to risk management.
- AI Adoption, Training, and Change Management: Facilitate AI training, education sessions, and knowledge-sharing forums for Risk users.
- AI Adoption, Training, and Change Management: Support change management efforts to embed AI tools and processes into day-to-day Risk workflows.
- AI Governance, Controls, and Risk Management: Work with firmwide AI governance teams to ensure appropriate control processes are established for Risk AI usage.
- AI Governance, Controls, and Risk Management: Support governance processes related to AI use case approval, data controls, model or code review, guardrails, testing, documentation, access management, change management, and ongoing monitoring.
- AI Governance, Controls, and Risk Management: Ensure AI solutions are implemented in accordance with applicable internal policies, risk standards, and regulatory expectations.
- AI Governance, Controls, and Risk Management: Help identify, document, and escalate potential risks related to AI adoption, including data quality, privacy, model performance, bias, operational risk, and control gaps.
About the company
Jefferies is a global, full‑service investment banking and capital markets firm that helps investors, companies, and governments with advisory services, sales and trading, research, and wealth and asset management. It uses a worldwide network of more than 40 offices to deliver market insights and financial solutions to clients. Its products include advisory services for mergers and restructurings, capital markets execution, securities research, and portfolio management for individuals and institutions. The goal is to guide clients through financial markets, raise capital, and grow wealth across geographies and asset classes.
Company Size
5,001-10,000
Company Stage
IPO
Headquarters
New York City, New York
Founded
1854
Get referred to Jefferies
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q3 2026 investment banking revenue hit $1.33 billion, up 17%.
- Equities revenue reached $626 million, driven by cash, electronic, and prime services.
- Hildene closes in 2026, adding $18 billion AUM and recurring credit income.
What critics are saying
- Point Bonita exposure to First Brands and Radiant World damaged asset-management trust.
- Asset-management revenue fell to $85.6 million in Q3 2026, down over 50%.
- Another First Brands-style blowup could trigger client redemptions and cripple Hildene integration.
What makes Jefferies unique
- SMBC owns about 20% and funds Jefferies with $2.5 billion facilities.
- Jefferies’ advisory and equities desks posted record Q3 2026 revenues.
- Japan joint venture with SMBC starts January 2027, combining research, trading, ECM.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Life Insurance
Wellness Program
Company News
Jefferies has identified three undervalued biotechnology stocks with strong commercial prospects despite challenging macroeconomic conditions. Delphia Therapeutics' oral psychedelic DT120 has produced three positive Phase III datasets for major depressive disorder and generalized anxiety disorder. Jefferies estimates $1.5 billion or more in peak sales per indication, implying a $9 billion valuation against the current $5 billion market cap. Axsome Therapeutics' Auvelity is approved for major depressive disorder and Alzheimer's agitation. Management's peak sales guidance of $8 billion for Auvelity suggests significant upside. BridgeBio Pharma is positioned to launch four blockbuster oral medications. Attruby could reach $3-4 billion in US peak sales, whilst three additional billion-dollar products will launch in 2027. The firm noted rising interest rates are pressuring small and mid-cap biotech companies, potentially shifting investor focus toward late-stage and commercial-stage names.
Jefferies has named Molbio Diagnostics its top pick in India's medical supplies sector, initiating coverage with a Buy rating and a price target of INR1,600. The brokerage projects revenue compound annual growth rate of 22% and profit after tax CAGR of 47% through FY26-29E. Founded in 2000, Molbio has developed the Truenat platform, an ultra-portable molecular diagnostics system that represents 86% of FY26 sales. The platform, built after 13 years of research, supports testing for 30 diseases and is patent-protected in over 100 countries. Jefferies expects margin expansion of approximately 830 basis points, driven by rising test-kit capacity utilisation and the scaling of Molbio's Optrascan platform to 11% of sales by FY29E.
Jefferies stung by soured bets at asset-management unit. 29 Sep 2026, 09:07 pm (Sept 29): Jefferies Financial Group Inc's asset-management unit revenue slumped more than 50% in the fiscal third quarter, sending shares down as the bank grapples with fallout from tumultuous investments. Net revenue in that business totalled US$85.6 million (RM349 million) in the three months through August, down from almost US$177 million in the same period a year earlier, according to a statement late Monday. That business has been dealing with soured bets on First Brands Group and Radiant World that the firm was exposed to through Leucadia Asset Management's Point Bonita fund. Shares of Jefferies dropped 1.1% in early New York trading, extending this year's decline to more than 25%. "We remain confident in the long-term outlook for the business as we continue to reposition the platform by reducing capital allocated to certain existing funds consistent with the strategy we outlined last fall when we announced our intent to acquire and fund a 50% interest in Hildene," chief executive officer Richard Handler and president Brian Friedman said in the statement. In 2025, Jefferies agreed to buy a 50% stake in Hildene Holding Co, a credit-focused asset manager that the bank had had a strategic relationship with for years. The firm's asset-management woes overshadowed a record quarter for Jefferies' stock traders and investment bankers. Equity-trading revenue surged 29% from a year earlier to US$626 million, boosted by cash and electronic trading as well as the prime services business that works with hedge funds. Revenue at the investment-banking business rose 17% to US$1.3 billion. That was driven by a 25% gain in the advisory unit and a 69% increase in the equity-underwriting business. In recent months, Radiant World has come under scrutiny amid allegations of fraud. Jefferies' exposure to Radiant World was less than US$300 million, Bloomberg previously reported. Fixed income. Jefferies' fixed-income trading business also had a tougher quarter, hit by a sluggish market that drove a 26% decrease in net revenue. Still, equity trading was "robust," even if questions are arising about how sustainable it can be, according to Vital Knowledge's Adam Crisafulli. The quarter was OK, he said. "Not amazing, not horrible." Earnings per share totalled US$1.08 in the period, surpassing the US$1 average estimate of analysts in a Bloomberg survey. Jefferies is the first of the major US banks to post third-quarter results, setting a benchmark for Wall Street firms that report in October. The results offer a look into how investment-banking businesses have held up despite market volatility. "We are very optimistic about the balance of 2026 and our momentum heading into 2027, supported by the breadth and strength of our current backlog and new business activity," Handler and Friedman said in the statement. The bank's quarter is also a positive sign for Wall Street's other equity-trading desks, many of which had already started hinting at how good the quarter was shaping up. Bank of America Corp. CEO Brian Moynihan said equity trading climbed in the quarter through the middle of September, while Goldman Sachs Group Inc's David Solomon said equity trading has remained "very strong." Fixed-income trading, however, has been softer in some parts of Wall Street. Bank of America has cautioned that revenue in the business was down and bouncing around. Uploaded by Magessan Varatharaja
Jefferies surpasses profit estimates on strong dealmaking. Jefferies Financial (JEF.N) has exceeded third-quarter profit estimates, propelled by strong performance in its advisory and stock underwriting businesses. The New York-based investment bank, which advises on deals, underwrites stock sales, and operates trading desks and an asset management business, reported profit attributable to shareholders of $260.6 million, or $1.08 per share, for the three months ended August 31. This comfortably surpassed the average analyst estimate of $1 per share, according to LSEG data. The company's investment banking revenue saw a significant 17% jump, reaching $1.33 billion, underpinned by record advisory business performance and robust equity underwriting. Revenue from its capital markets segment, encompassing Jefferies' trading desks, also climbed 11% to $802 million, driven by record equities trading. These results offer an early indication of broader investment banking trends on Wall Street, arriving ahead of major US banks' earnings reports in coming weeks, and align with a global dealmaking environment that has exceeded $4 trillion this year. Despite the overall strong showing, Jefferies' asset management business faced headwinds. Fees and investment return revenue in this division shrank considerably to $34 million, down from $84 million a year earlier. This decline reflects weaker performance across several fund strategies, notably Point Bonita, which held exposure to the bankrupt auto-parts supplier First Brands. Looking forward, CEO Richard Handler and President Brian Friedman expressed optimism for 2026 and momentum into 2027, citing strong backlog and new business activity, while also affirming confidence in the long-term outlook for the asset management platform. However, the firm's shares were down 1.5% in extended trading, contributing to an approximate 24% decline this year.
Sep 29th, 2026 Jefferies stung by soured bets at asset-management unit. Jefferies Financial Group's asset-management unit revenue slumped more than 50% in the fiscal third quarter, totaling $85.6 million in the three months through August. Bloomberg Intelligence's Neil Sipes has more. Top video. Available on: